Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

MICONAZOLE IMPURITY G CRS (0.02 MG)

MICONAZOLE IMPURITY G CRS (0.02 MG)

ND

DISCOVER
CALCIUM CARBONATE FOR EQUIPMENT QUALIFICATION CRS (260 MG)

CALCIUM CARBONATE FOR EQUIPMENT QUALIFICATION CRS (260 MG)

ND

DISCOVER
ATORVASTATIN IMPURITY MIXTURECRS (0.03 MG)

ATORVASTATIN IMPURITY MIXTURECRS (0.03 MG)

NA

DISCOVER
TRYPSIN FOR APROTININ ASSAY BRP (100 MG)

TRYPSIN FOR APROTININ ASSAY BRP (100 MG)

ND

DISCOVER
DYDROGESTERONE FOR IMPURITY AIDENTIFICATION CRS (0.002 MG)

DYDROGESTERONE FOR IMPURITY AIDENTIFICATION CRS (0.002 MG)

ND

DISCOVER
DOMPERIDONE IMPURITY MIXTURE CRS (0.04 MG)

DOMPERIDONE IMPURITY MIXTURE CRS (0.04 MG)

NA

DISCOVER
BROMAZEPAM FOR SYSTEM SUITABILITY A CRS - * PSY (BROMAZEPAM)

BROMAZEPAM FOR SYSTEM SUITABILITY A CRS - * PSY (BROMAZEPAM)

ND

DISCOVER
ATORVASTATIN CALCIUM CRS (150MG)

ATORVASTATIN CALCIUM CRS (150MG)

344423-98-9

DISCOVER
ECHINACEA DRY EXTRACT FOR SYSTEM SUITABILITY HRS (15 MG)

ECHINACEA DRY EXTRACT FOR SYSTEM SUITABILITY HRS (15 MG)

ND

DISCOVER
GONADORELIN FOR SYSTEM SUITABILITY A CRS (1 MG)

GONADORELIN FOR SYSTEM SUITABILITY A CRS (1 MG)

ND

DISCOVER
ATORVASTATIN FOR PEAK IDENTIFICATION A CRS (15 MG)

ATORVASTATIN FOR PEAK IDENTIFICATION A CRS (15 MG)

ND

DISCOVER
THIOPENTAL IMPURITY MIXTURE CRS - * PSY (PENTOBARBITAL) (0.0

THIOPENTAL IMPURITY MIXTURE CRS - * PSY (PENTOBARBITAL) (0.0

ND

DISCOVER